Breaking News

Onyx Appoints Global R&D Executive

February 15, 2013

Cagnoni will be responsible for managing R&D and technical operations

Pablo J. Cagnoni, M.D., has been appointed Onyx’s executive vice president, Global Research & Development and Technical Operations, effective March 2013. Dr. Cagnoni will be responsible for managing the R&D organization as well as Technical Operations. He will report to N. Anthony Coles, M.D., chairman and chief executive officer of Onyx.
 
"Pablo's broad leadership and management skills, combined with his track record of developing some of the most successful cancer therapies, including Tarceva, Afinitor, and Folotyn, make him the ideal person to lead our efforts in the development of innovative oncology medicines," said Dr. Coles. "He brings world-class R&D leadership as Onyx delivers on its vision of becoming a leading global oncology company committed to bringing new therapies to patients living with cancer."
 
Prior to joining the company, Dr. Cagnoni was senior vice president and Global Head of Clinical Development of Novartis Oncology. He was responsible for all clinical development, clinical operations, clinical pharmacology and science activities for the oncology development pipeline. He oversaw the U.S., European and Japanese regulatory submissions and approvals of Afinitor, Tasigna, Signifor, Exjade, Jakavi and Glivec in various indications.
  • When Quality Meets Confidence

    When Quality Meets Confidence

    Dr. Fadia AlKhalil, Vice President of Global Business Development for Laboratory Services, SGS ||November 9, 2016
    A look at global account management for R&D outsourcing

  • CROs and Today’s  R&D Landscape

    CROs and Today’s R&D Landscape

    Kristin Brooks, Associate Editor, Contract Pharma||November 9, 2016
    John Lewis of ACRO discusses opportunities, challenges, and the future CRO

  • The Human Parts of Mouse Models

    The Human Parts of Mouse Models

    Julia Schueler, Head of in vivo Operations, Oncotest, a Charles River company ||October 11, 2016
    The PDX model system has come back into focus